[EN] SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME [FR] COMPOSÉS 2,2'-BIPYRIMIDINYL SUBSTITUÉS, ANALOGUES DE CEUX-CI, ET PROCÉDÉS LES UTILISANT
[EN] SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME [FR] COMPOSÉS 2,2'-BIPYRIMIDINYL SUBSTITUÉS, ANALOGUES DE CEUX-CI, ET PROCÉDÉS LES UTILISANT
Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
申请人:NPS PHARMACEUTICALS, INC.
公开号:US20030013715A1
公开(公告)日:2003-01-16
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
The present invention provides compounds of formula (I)
wherein R
a
, R
b
, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
29
are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY
申请人:Connolly Stephen
公开号:US20100022491A1
公开(公告)日:2010-01-28
The present invention provides compounds of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Ra, Rb, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
29
are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors
申请人:Harling John David
公开号:US20090099231A1
公开(公告)日:2009-04-16
The present invention provides pyrrolidinone derivatives as Factor Xa inhibitors and pharmaceutical compositions comprising the same. The invention also relates to processes for the preparation of such compounds, and the use of such compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.